help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campioni, D.
Right arrow Articles by Zauli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campioni, D.
Right arrow Articles by Zauli, G.
(American Journal of Pathology. 2005;166:557-563.)
© 2005 American Society for Investigative Pathology

Evidence for a Role of TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Anemia of Myelodysplastic Syndromes

Diana Campioni*, Paola Secchiero{dagger}, Federica Corallini{dagger}, Elisabetta Melloni{dagger}, Silvano Capitani{dagger}, Francesco Lanza* and Giorgio Zauli{ddagger}

From the Department of Biomedical Sciences and Advanced Therapies,* Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara; the Department of Morphology and Embryology,{dagger} Human Anatomy Section, University of Ferrara, Ferrara; and the Department of Normal Human Morphology,{ddagger} University of Trieste, Trieste, Italy

Myelodysplastic syndromes (MDS) are characterized by impaired erythropoiesis, possibly caused by proapoptotic cytokines. We focused our study on the cytokine TRAIL (TNF-related apoptosis-inducing ligand), which has been shown to exhibit an anti-differentiation activity on erythroid maturation. Immunocytochemical analysis of bone marrow mononuclear cells (BMMC) showed an increased expression of TRAIL in MDS patients with respect to acute myeloid leukemia (AML) patients and normal BM donors. TRAIL expression was increased predominantly in myeloid precursors of granulocytic lineage and in a subset of monocytes and pro-erythroblasts. Significant levels of soluble TRAIL were released in 21 of 68 BMMC culture supernatants from MDS patients. On the other hand, TRAIL was detected less frequently in the culture supernatants of AML (4 of 33) and normal BMMC (0 of 22). Analysis of peripheral blood parameters revealed significantly lower levels of peripheral red blood cells and hemoglobin in the subset of patients whose BMMC released TRAIL in culture supernatants compared to the subgroup of patients who did not release TRAIL. Moreover, TRAIL-positive BMMC culture supernatants inhibited the differentiation of normal glycophorin A+ erythroblasts generated in serum-free liquid phase. Thus, increased expression and release of TRAIL at the bone marrow level is likely to impair erythropoiesis and to contribute to the degree of anemia, the major clinical feature of MDS.




This article has been cited by other articles:


Home page
 haematolHome page
N. Galili, S. A. Qasim, and A. Raza
Defective ribosome biogenesis in myelodysplastic syndromes
Haematologica, October 1, 2009; 94(10): 1336 - 1338.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. I. Maratheftis, E. Andreakos, H. M. Moutsopoulos, and M. Voulgarelis
Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes
Clin. Cancer Res., February 15, 2007; 13(4): 1154 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Braun, G. Carvalho, A. Coquelle, M.-C. Vozenin, P. Lepelley, F. Hirsch, J.-J. Kiladjian, V. Ribrag, P. Fenaux, and G. Kroemer
NF-{kappa}B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome
Blood, February 1, 2006; 107(3): 1156 - 1165.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology.